

Phytochemical Assay and Antiplatelet Activity of Fractions of Velvet Bean Seeds (*Mucuna pruriens* L.)

WAHYU WIDOWATI¹*, HANA RATNAWATI², UDJU DJUNAEDI RUSDI³,
WAHYU WINARNO⁴, VICTOR IMMANUEL⁵

¹Department of Chemistry, Faculty of Mathematic and Natural Sciences, University of Jenderal Achmad Yani,
Jalan Terusan Jenderal Sudirman, Cimahi 40533, Indonesia

²Medical Research Center, Faculty of Medicine, Maranatha Christian University,
Jalan Prof. Drg. Suria Sumantri 65, Bandung 40164, Indonesia

³Department of Microbiology, Faculty of Medicine, University of Jenderal Achmad Yani,
Jalan Terusan Jenderal Sudirman, Cimahi 40533, Indonesia

⁴Department of Agricultural Production, State Polytechnic of Jember, Jalan Mastrip, Jember 68101, Indonesia

⁵Laboratory of Clinical Pathology, Hasan Sadikin Hospital, Jalan Pasteur 38, Bandung 40161, Indonesia

Received February 8, 2010/Accepted June 4, 2010

Platelet aggregation is an important factor contributing to the formation of thrombus due to an uncontrolled blood clotting. An antiplatelet agent is a compound which decreases platelet aggregation and inhibits thrombus formation. The objectives of this study were to determine the class of compound employing phytochemical assay and to determine the *in vitro* antiplatelet activity of four fraction, namely hexane, ethyl acetate, butanol, and water fractions of velvet bean seeds (*Mucuna pruriens* L.) using epinephrine (EPN) as agonist of platelet aggregation. The antiplatelet activities were tested in human platelet rich plasma with hyperaggregation. To determine the activities, EPN was arranged at 4 level of concentrations (300, 150, 75, and 30 μ M), and antiplatelet agents were at 500 μ g/ml. The results indicated that ethyl acetate, butanol and water fraction contained high flavonoids and moderate phenols. The water, butanol and ethyl acetate fractions of velvet bean seeds exhibited potential inhibition of EPN-induced platelet aggregation at all concentrations. The strongest antiplatelet agent was water fraction and had the same antiplatelet activity as aspirin at level 150, 75, and 30 μ M of EPN. Butanol fraction had the same antiplatelet activity as aspirin at the lowest EPN (30 μ M).

Key words: platelet, *Mucuna pruriens* L., epinephrine, flavonoid, aspirin

INTRODUCTION

Hyperaggregability is one of the risk factors in pathogenesis of thrombosis and atherosclerosis, the most common cause of premature death in developed world as many as 30% of all deaths (Olas & Wachowicz 2005). Platelets play a crucial role not only in homeostasis but also in the development of cardiovascular disease (CVD). The increasing acute clinical manifestations of coronary atherosclerotic disease are caused by plaque disruption and subsequent platelet-thrombus formation (O'Kennedy *et al.* 2006). Inhibiting the platelet aggregation is one of the efforts for preventing cardiovascular disease. Atherosclerosis is the pathological consequence from the modification of oxidized LDL in arterial wall which can be stimulated by free radicals. Preventing the oxidation of LDL has a meaning to prevent coronary heart disease. Giving antioxidant supplement both vitamin E and flavonoid (vegetable, fruit, tea) to CVD patients increase the defense towards the attack of free radicals (Olas & Wachowicz 2005).

*Corresponding author. Phone: +62-22-6078392,
Fax: +62-22-6652069, E-mail: wahyu_w60@yahoo.com

It has been found that platelet inhibitory drugs, such as aspirin, physiologically reduce the incidence of myocardial infarction, stroke, and death from cardiovascular diseases in prevention trials. A number of prospective randomized clinical trials have shown that 50-500 mg of aspirin per day reduces the risk of primary or secondary cardiovascular events (Olas & Wachowicz 2005). The usage of aspirin has negative side effects: low dose aspirin increases the risk of major bleeding and intestinal ulceration, and for a prolong therapy, it usually causes many side effect (Schrör 1997; Ohmori *et al.* 2006). The aspirin resistance is a clinical inability of aspirin to protect individuals from arterial thrombotic events or when laboratory methods indicate the failure of aspirin to inhibit platelet activity (Cattaneo 2004; Ohmori *et al.* 2006). It is estimated that between 8-45% of patients suffering an ischemic stroke or cardiovascular disease are aspirin resistant (McKee *et al.* 2002; Ohmori *et al.* 2006). It is an urgent need to search natural compounds having antiaggregation properties with minimal side effects and safer. One of the natural compounds with antiplatelet activity is flavonoid. It can prevent atherosclerosis, endothelial damage, leukocyte activation, adhesive

aggregation, and platelet secretion (Koshy *et al.* 2001; Bucki *et al.* 2003). Natural antioxidants having minimal side effects can be obtained from plants containing phenolic and polyphenolic compounds, such as flavonoids (Bucki *et al.* 2003; Koleckar *et al.* 2008). Flavonoids bioavailability and its relationship with antioxidant and antiplatelet activity, resulting in cardiovascular protection (Violi 2002).

The natural compounds including flavonoids can be obtained ubiquitously in Indonesia, such as in velvet bean *Mucuna pruriens* L., and it has not been used optimally. Previous research demonstrated the total polyphenolic content of the methanol extract of *M. pruriens* was 33.04 mg/g gallic acid, a noticeable amount of total phenols (Rajeshwar *et al.* 2005). *M. pruriens* contains isoflavones such as daidzin 0.041; glycitein 0.011; genistein 0.050; aglucones total 0.131 mg/l (Handajani 2001). Methanol extract of *M. pruriens* (MEMP) has high antioxidant activity (Rajeshwar *et al.* 2005).

MATERIALS AND METHODS

The four fractions (hexane, ethyl acetate, n-butanol, and water fraction) were obtained from ethanol extract of velvet bean seeds (*M. pruriens* L.).

The four fractions of velvet bean seeds were tested by phytochemical assay including flavonoid assay, phenolic, saponin, triterpenoid, steroid, terpenoid, tanin, and alkaloid assay. The four fractions and aspirin as positive control were diluted with dimethyl sulfoxide (DMSO 1%) achieving at level 500 µg/ml. Epinephrine (EPN) was diluted with distilled water at various concentrations of 300, 150, 75, 30 µM. Platelet rich plasma (PRP) obtained from hyperaggregation individual (Helena Laboratories 2008).

9 ml blood was collected from hyperaggregation individual and added with 1 ml 3.8% sodium citrate as anticoagulant. The blood was centrifuged at 100 × g for 10 minutes. The platelet rich plasma (PRP) was removed from the cells with a plastic pipette and placed in a plastic tube. The PRP was maintained at room temperature for 30 minutes. Platelet poor plasma (PPP) was prepared by recentrifuging the remaining blood samples at 1600 × g for 10 minutes. PPP was then removed, placed in a plastic tube, and the tube was maintained at room temperature (Chun-Han *et al.* 1993; Helena Laboratories 2008).

Aggregation activity was measured by Platelet Aggregation Chromogenic Kinetic System (PACKS-4). 450 µl of PPP was pipetted into a cuvette. 450 µl PRP and

40 µl the antiplatelet agents (aspirin, hexan fraction, ethyl acetate fraction, butanol fraction, water fraction) were also pipetted into cuvettes with stir bar and incubated at 37 °C for 3-5 minutes. The PPP and PRP cuvettes were inserted into appropriate channels and the instrument was set up. 50 µl of the aggregating reagent dilutions (Epinephrine) at level 300, 150, 75, 30 µM was added to the PRP cuvette and the percent aggregation was recorded (Helena Laboratories 2008).

All treatments consisted of 20 levels arranged in a factorial design. The first factor was the inducing concentration (four level concentrations) and the second factor was the antiplatelet agent (five level antiplatelet agents). The treatments were replicated three times. To verify the statistical significance of the parameters, the data was calculated for the values of means and standard deviation ($M \pm SD$) and 95% confidence interval (CI) of means. To compare several treatments, we used analysis of variance (ANOVA) with two-factorial completely randomized design. P-values of less than 0.05 were considered as statistically significant. Furthermore, to know the difference of means among treatments and to know the best treatment, we used Duncan's Post-Hoc test 95% confidence interval. Statistical analysis used SPSS 16.0 program.

RESULTS

The phytochemical assay showed that hexane fraction of velvet bean seeds contained lowest flavonoids and phenolics compound compared with the other fractions (Table 1). Ethyl acetate, butanol and water fractions contained high flavonoid and moderate phenolic compounds, but they did not contain terpenoid and triterpenoid compounds. Butanol fraction contained the highest tanin compared with the other fractions. Water fraction contained moderate alkaloids and butanol and ethyl acetate fractions contained less alkaloids. Hexane, ethyl acetate and butanol fractions contained less steroids. Butanol and water fractions contained less saponins, whereas hexane and ethyl acetate fractions did not contain saponins (Table 1).

Observing the antiplatelet activity, epinephrine (EPN) agonist induced platelet aggregation at all level concentrations, the lower concentration of EPN as agonist caused the reduction of platelet aggregation (Table 2). Aspirin as positive control decreased platelet aggregation at all concentrations of EPN. After aspirin, the most effective fraction showing the antiplatelet activity was

Table 1. The result of phytochemical assay of velvet bean seed fractions (hexane fraction, ethyl acetate, butanol, and water fraction)

Sample (fractions)	Compound content							
	Tanins	Flavonoids	Phenols	Saponins	Terpenoids	Triterpenoids	Steroids	Alkaloids
Hexane	-	+	+	-	+	-	+	-
Ethylacetate	++	+++	++	-	-	-	+	+
Buthanol	+++	+++	++	+	-	-	+	+
Water	++	+++	++	+	-	-	-	++

+++; high content, ++; moderate content, +; less content, -; undetected.

Table 2. The antiplatelet activity of velvet bean seed fractions

Antiplatelet agents	EPN 300 ì M	EPN 150 ì M	EPN 75 ì M	EPN 30 ì M
Control (Hyperaggregation)	82.633 ± 8.228b D	74.067 ± 3.761ab C	68.267 ± 9.215a C	66.067 ± 2.732a C
Aspirin	31.333 ± 8.912a A	28.600 ± 4.029a A	27.433 ± 1.756a A	27.000 ± 1.825a A
Hexane fraction	68.233 ± 9.127b CD	60.767 ± 3.272ab B	55.033 ± 4.168a B	53.933 ± 4.509a B
Ethyl acetate fraction	69.733 ± 5.064b D	69.000 ± 4.784b C	69.800 ± 5.237b C	58.867 ± 2.950a B
Butanol fraction	54.433 ± 8.315b B	54.367 ± 2.318b B	51.033 ± 10.934b B	31.133 ± 3.134a A
Water fraction	47.600 ± 8.0206b B	34.067 ± 4.350a A	31.267 ± 3.027a A	27.500 ± 4.939a A

The data showed means ± standard deviation. The different small letters at the same row (among EPN concentrations) and capital letters at the same column (among antiplatelet agents) show significant at the 5% (Duncan's Post Hoc test).

the water fraction followed by butanol fraction at all concentrations of EPN, except at 30 mM of EPN. The antiplatelet aggregation at 30 ì M concentration of EPN showed similar activity among aspirin, water fraction and butanol fraction of velvet bean (Table 2).

DISCUSSION

Previous research showed that velvet bean seeds are rich in novel alkaloids, saponins, and sterols. The seeds of all *Mucuna* species contain a high concentration of L-dopa; velvet bean seeds contain 7-10% L-dopa (Del Carmen *et al.* 1999). Crude content of velvet bean showed the presence of alkaloid, flavonoid, tannin, saponin, quinone, and steroid/triterpenoid (Yulizia 2008). The velvet bean seeds contain the bioactive alkaloids mucunine, mucunadine, mucuadinine, pruriendine and nicotine, ß-sitosterol, glutathione, lecithin, oils, venolic and gallic acids. The seeds with seed coat showed the presence of a number of bioactive substances including tryptamine, alkylamines, steroids, flavonoids, coumarins, cardenolides. The major phenolic constituent of *Mucuna* beans was L-dopa (Rajeshwar *et al.* 2005). The phenolic and flavonoid contents from our research verify the previous research, but alkaloids, saponins, and sterols concentration of *Mucuna* seeds can not be validated. The different content of alkaloids and saponins may be caused by different farming of strain of *Mucuna*.

Antiplatelet agents (aspirin and four fractions of velvet bean) decreased the EPN-induced platelet aggregation compared with control (hyperaggregation individual) at all level concentration of epinephrine (Table 2). The concentration level of EPN as an inducer affects the platelet aggregation, the higher concentration of EPN the higher the platelet aggregation (Hoffbrand & Pettit 1996). Blood platelets can be activated by different compounds including coagulation factors (thrombin), hormones (epinephrine, vasopresin), low molecular weight substances [serotonin, adenosine diphosphate (ADP), lipid derivatives (platelet aggregating factor (PAF), thromboxane A2 (TXA2)], and other protein substances (collagen or immune complexes). The responses of platelet include mainly adhesion (to foreign surfaces such as

collagen or glass), shape change, aggregation and secretion of active compounds from three different storage granules (dense granules, a-granules and lysosomes), shedding of microvesicles, formation of platelet procoagulant activity and retraction of fibrin clots (Willoughby *et al.* 2002; Olas & Wachowicz 2005; Fogari & Zoppi 2005). Epinephrine stimulates human blood platelets by an α_2 -adrenergic receptor mechanism (Kjeldsen *et al.* 1995). α_2 -adrenergic receptors may more directly activate phospholipase A₂ via release of G protein $\beta\gamma$ -subunits. Phospholipase A₂, which releases arachidonic acid from platelet lipids to form thromboxane A₂ (TXA₂), plays an important role in epinephrine-mediated platelet activation (Kjeldsen *et al.* 1995). Epinephrine agonists require aggregation for secretion to occur. After platelet activation induced by an agonist, intracellular signalling is necessary for cytoskeletal reorganisation, fibrinogen receptor exposure (integrin α IIb β 3), and granule secretion to occur. Two differential pathways central to platelet activation are the phosphoinositide hydrolysis pathway and the eicosanoid synthesis pathway (Olas & Wachowicz 2005). The previous research showed that infused epinephrine in doses of 0.1 and 0.2 μ g/kg per minute on 40 healthy men aged 20 to 40 years increased in the capacity for TXB₂ production by platelets (Kjeldsen *et al.* 1995). Infused epinephrine up to 0.04 μ g/kg per minute in healthy men, increased platelet count and size (Lande *et al.* 1988). Epinephrine in the presence of fibrinogen and Ca²⁺ (*in vitro*) induces both primary and secondary aggregation, potentiates aggregation (Kjeldsen *et al.* 1995).

Aspirin is the best antiplatelet agent at all level of inducer concentrations and as an anti-thrombotic compounds through the inhibition of platelet cyclooxygenase-1 (COX-1) by irreversible acetylation of a specific serine moiety, thereby blocking the formation of thromboxane A₂ (TXA₂) for the lifetime of the platelets (McKee *et al.* 2002; Ohmori *et al.* 2006).

Water fraction of velvet bean seeds is comparable to aspirin because of the moderate content of phenols and the high content of flavonoids (Table 1). Phenols and flavonoids show commonly high antioxidant and antiplatelet activities. The previous research showed that

methanol extract of velvet bean seeds contained a noticeable amount of total phenols (Rajeshwar *et al.* 2005). Phenolic compounds exhibit a wide range of biological effects, including antiplatelet, anti-inflammatory, anticancer, antimutagenic, and antifungal properties. It is also a potent antioxidant, reactive oxygen species scavenger and metal chelators (Olas & Wachowicz 2005). The extract contains many compounds including flavonoids, tanins, phenols, saponins, terpenoids, triterpenoids, steroids, alkaloids. Each fraction of velvet bean contains different compounds (Table 1). This result confirm the previous study that *M. pruriens* contained isoflavones (the subclass of flavonoid) (Handajani 2001). Eriodictyol and patuletin are flavonoids from *Leuzea carthamoides* inhibiting platelet aggregation with agonist collagen (COL) and arachidonic acid (AA) (Koleckar *et al.* 2008).

Rutin is a flavonoid inhibiting platelet aggregation in human platelets stimulated by COL agonist depend on its concentration (250 and 290 μ M) (Sheu *et al.* 2004). The antiplatelet activity of rutin (flavonoid) may involve the following pathways: rutin inhibits the activation of phospholipase C, followed by inhibition of protein kinase C activity and TXA₂ formation, thereby leading to inhibition of the phosphorylation of platelet protein of M(r) 47000 (P47) a marker of protein kinase C activation and intracellular Ca²⁺ mobilization, and finally resulting in inhibition of platelet aggregation (Sheu *et al.* 2004). The *in vitro* combination of 2 flavonoids, namely quercetin and catechin, demonstrated that they are synergistic in reducing platelet formation of H₂O₂ and inhibiting platelet function by interfering the activation of phospholipase C pathway (Violi 2002). Flavonoid bioavailability and its relationship with antioxidant activity and platelet function (Violi 2002). Flavonoids have antioxidant activity, inhibits platelet aggregation and production of superoxide anion, resulting in cardiovascular protection (Violi 2002).

Catechin and eugenol (flavonoids) also inhibit cyclooxygenase (COX) activities and platelet aggregation (Huss *et al.* 2002). The isolation of flavonoids from *Cephalotaxus wilsoniana* (Cephalotaxaceae) had antiplatelet and anti-inflammatory effect (Wu *et al.* 2007). The ginkgetin flavonoid was isolated from *Cephalotaxus wilsoniana* and *Justicia species* had inhibitory effect on cyclooxygenase-1 (COX-1). The flavonoids including ginkgetin, taiwanhomoflavone C, justicidin B, and justicidin D were isolated from *Cephalotaxus wilsoniana* and *Justicia* showed inhibition of secondary aggregation induced by adrenaline (Wu *et al.* 2007).

The butanol and water fractions of velvet bean seeds show promising antiplatelet activities. These results suggest that the antiplatelet activities of the fractions may be mediated by TXA₂ receptor blockade with TXA₂ synthase inhibiting and suppressing cytosolic [Ca²⁺] mobilization (Jin *et al.* 2005), and inhibiting the activation of phospholipase C, followed by inhibition of protein kinase C activity and TXA₂ formation, thereby leading to inhibition of the phosphorylation of P47 and intracellular

Ca²⁺ mobilization, finally resulting in inhibition of platelet aggregation (Mc Kenzie 2004; Sheu *et al.* 2004). TXA₂ formation cause the bond between platelets is weak and platelet aggregation is reversible (primer aggregation), secondary aggregation need longer time and produces irreversible aggregation platelet (Mc Kenzie 2004). Supplementation studies with polyphenol-rich foods or extracts indicate that the compounds may exert effects *in vivo* as well. For instance, the ingestion of dealcoholized red wine, grape juice, or polyphenol extracts reduced blood pressure and inhibited platelet aggregation in laboratory animals (Erlund *et al.* 2008).

The flavonoid-rich beverages such as red wine and purple grape juice are vasodilators and improve endothelial function, probably because of a nitric oxide-dependent mechanism (Lin *et al.* 2007).

Quercetin and catechin are flavonoids antioxidant, synergistically inhibit platelet function (*in vitro* assay) by blunting the release of hydrogen peroxide (H₂O₂) from platelets, subsequently reducing phospholipase C activation, calcium mobilization, and inositol phosphate synthesis. Flavonoids inhibit platelet aggregation because of their antioxidant activity, either by inhibiting the formation of endogenous mediators derived from phospholipid peroxidation, by blocking enzymatic free radical production, or by reducing platelet sensitivity to agonists by preventing lipid peroxidation (Murphy *et al.* 2003). Based on the experimental model of diabetes tested animal, the combination of acetylsalicylic acid and α -tocopherol as antioxidant led to beneficial changes that can help protect tissues from thrombotic incidents (Gonzales-Correa *et al.* 2006). Various agonists may stimulate platelet reactive oxygen species (ROS) production and aggregation, by regulating AA metabolism or via COX inhibition (Iuliano *et al.* 1997). In the presence of haemoglobin, ROS-induced platelet aggregation is enhanced (Iuliano *et al.* 1992). The resting platelets also generated a low amount of ROS. AA stimulates platelet ROS production, which is inhibited by hydroxychavicol flavonoid (HC), supporting HC flavonoid as a ROS scavenger (Chang *et al.* 2002). Our data (Table 2) showed that water fraction, butanol and ethyl acetate fraction of velvet bean seeds decreased platelet aggregation (as an antiplatelet activity) probably due to antioxidant activities. Previous research showed that *M. pruriens* had an ability to scavenge DPPH radicals, ABTS radicals and ROS. Velvet bean seeds significantly inhibit the oxidation of lipids and deoxyribose sugar. *M. pruriens* exhibited bivalent iron chelating activity (Dhanasekaran *et al.* 2008). Methanol extract of *M. pruriens* shows strong antioxidant activity by inhibiting DPPH and hydroxyl radicals, nitric oxide and scavenging superoxide anion, scavenging hydrogen peroxide, and reducing power activities when compared with different standards such as BHT, L-Ascorbic acid, curcumin, quercetin, and α -tocopherol (Rajeshwar *et al.* 2005). AA-induced thromboxane production or induced by the other agonists is not solely mediated by ROS production. The other possible reason

is that platelet ROS production can be mediated by COX as well as other enzymes such as platelet isoforms of NADPH oxidase, xanthine oxidase, mitochondrial respiration (Krotz *et al.* 2002). HC flavonoid inhibits the enzymes responsible for platelet ROS formation (Finazzi-Agro *et al.* 1982; Chang *et al.* 2007).

Aspirin showed higher antiplatelet activity compared with butanol and water fraction of velvet bean seeds, particularly at high concentration of epinephrine. Because aspirin is pure compound, it will produce high antiplatelet activity. The butanol and water fractions of velvet bean seeds contain complex compounds. To obtain the pure compound with high antiplatelet activity is required on further study.

The ethyl acetate, butanol, and water fraction contained high flavonoid and moderate phenol. The water, butanol, and ethyl acetate fraction of velvet bean seeds exhibited potential inhibition of EPN induced platelet aggregation at all concentrations. The strongest antiplatelet was water fraction and had similar antiplatelet activities with aspirin at level 150, 75, and 30 μ M of EPN inducer. Butanol fraction had similar antiplatelet activity with aspirin at lowest EPN inducer (30 μ M).

ACKNOWLEDGEMENT

We are grateful to Directorate General for Higher Education, Ministry of National Education of Republic Indonesia, for Research Grant of Hibah Bersaing (2007, 2008) for financial support.

REFERENCES

- Bucki R, Pastore JJ, Giraid F, Sulpice JC, Janmey PA. 2003. Flavonoid inhibition of platelet procoagulant activity and phosphoinositide synthesis. *J Thromb Haemost* 1:1820-1828.
- Cattaneo M. 2004. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. *Arterioscler Thromb Vasc Biol* 24:1980-1987.
- Chang MC, Uang BJ, Wu HL, Lee JJ, Hahn LJ, Jeng JH. 2002. Inducing the cell cycle arrest and apoptosis of oral KB carcinoma cells by hydroxychavicol: roles of glutathione and reactive oxygen species. *Br J Pharmacol* 135:619-630.
- Chun-Han L, Wen-Lian S, Feng-Nien K, Che-Ming T. 1993. Antiplatelet activity of some prenylflavonoids. *Biochem Pharmacol* 45:509-512.
- Dhanasekaran T, Tharakan B, Manyam BV. 2008. Antiparkinson drug *Mucuna pruriens* shows antioxidant and metal chelating activity. *Phytother Res* 22:6-11.
- Erlund I, Koli R, Alfthan G, Marniemi J, Puukka P, Mustonen P, Mattila P, Jula A. 2008. Favorable effects of berry consumption on platelet function, blood pressure, and HDL cholesterol. *Am J Clinical Nutrition* 87:323-331.
- Finazzi-Agro A, Menichelli A, Persiani M, Biancini G, Del Principe D. 1982. Hydrogen peroxide release from human blood platelets. *Biochim Biophys Acta* 718:21-25.
- Fogari R, Zoppi A. 2005. Is the effect of antihypertensive drugs on platelet aggregability and fibrinolysis clinically relevant? *Am J Cardiovasc Drugs* 5:211-223.
- Gonzalez-Korera JA, Arrebola MM, Guerrero A, Canada MJ, Marin JM, De la Cuesta SF, De la Cruz JP. 2006. Antioxidant and antiplatelet effects of the alpha-tocopherol-aspirin combination in type 1-like diabetic rats. *Life sciences* ISSN 0024-3205 CODEN LIFSAK .
- Handajani S. 2001. Indigenous mucuna tempe as functional food. *Asia Pacific J Clin Nutr* 10:222-225.
- Helena Laboratories. 2008. Helena platelet aggregation system. Beaumont: Texas.
- Hoffbrand AV, Pettit JE. 1996. *Essential Haematology*. Terjemahan Iyan Darmawan. 2nd. Jakarta: EGC.
- Huss U, Ringbom T, Perera P, Bohlin L, Vasange M. 2002. Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay. *J Nat Prod* 65:1517-1521.
- Iuliano L, Colavita AR, Leo R, Pratico D, Violi F. 1997. Oxygen free radicals and platelet activation. *Free Radical Biol Med* 22:999-1006.
- Iuliano L, Violi F, Pedersen JZ, Pratico D, Rotilio G, Balsano F. 1992. Free radical-mediated platelet activation by hemoglobin released from red blood cells. *Arch Biochem Biophys* 299:220-224.
- Jin YR, Cho MR, Ryu CK, Chung JH, Yuk DJ, Hong JT, Lee KS, Lee M, Lim Y, Yun YP. 2005. Antiplatelet activity of J78 (2-Chloro-3-[2'-bromo, 4'-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca²⁺ mobilization. *J Pharmacol Exp Ther* 312:214-219.
- Kjeldsen SE, Weder AB, Egan BE, Neubig R, ZweiferAJ, Julius S. 1995. Effect of Circulating epinephrine on platelet function and hematocrit. *Hypertension* 25:1096-1105.
- Koleckar V, Brojerova E, Rehakova Z, Kubikova K, Cervenka F, Kuca K, Jun D, Hronek M, Opletalova V, Opletal L. 2008. In vitro antiplatelet activity of flavonoids from *Leuzea carthamoides*. *Drug Chem Toxicol* 31:27-35.
- Koshy AS, Anila L, Vijayalaksmi NR. 2001. Flavonoids from *garcinia combagia* lower lipid levels in hypercholesterlemic rats. *Food Chemistry* 72:289-294.
- Lande K, Kjeldsen SE, Westheim A, Hjermann I, Eide I, Gjesdal K. 1988. Increased platelet and vascular smooth muscle reactivity to low-dose adrenaline infusion in mild essential hypertension. *J Hypertens* 6:219-225.
- Lin J, Rexrode KM, Hu F, Albert CM, Chae CU, Rimm EB, Stampfer MJ, Manson JAE. 2007. Dietary intakes of flavonols and flavones and coronary heart disease in US women. *Am J Epidemiol* 165:1305-1313.
- McKee SA, Sane DC, Deliangyris EN. 2002. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. *Thromb Haemost* 88:711-715.
- McKenzie SB. 2004. Clinical Laboratory Hematology. New Jersey: Pearson Education, Inc.
- Murphy KJ, Chronopoulos AK, Singh I, Francis MA, Moriarty H, Pike MJ, Turner AH, Mann NJ, Sinclair AJ. 2003. Dietary flavanols and procyanidin oligomers from cocoa (*Theobroma cacao*) inhibit platelet function. *Am J Clinical Nutrition* 77:1466-1473.
- O'Kennedy N, Crosbie L, van Lieshout M, Broom JI, Webb DJ, Duttaroy AK. 2006. Effects of antiplatelet components of tomato extract on platelet function in vitro and ex vivo: a time-course cannulation study in healthy humans. *Am J Clinical Nutrition* 84:570-579.
- Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, Ozakis Y, Sakata Y. 2006. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. *J Thromb Haemost* 4:1271-1278.
- Olas B, Wachowicz B. 2005. Resveratrol, a phenolic antioxidant with effects on blood platelet functions. *Platelets* 16:251-260.
- Rajeshwar Y, Kumar GPS, Gupta M, Mazumder UK. 2005. Studies in vitro antioxidant activities of methanol extract of *Mucuna pruriens* (Fabaceae) seeds. *Eur Bull Drug Res* 13:31-39.
- Schrör K. 1997. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. *Semin Thromb Haemost* 23:349-356.

- Sheu JR, Hsiao G, Chou PH, Shen MY. 2004. Mechanisms involved in the antiplatelet activity of rutin, a glycoside of the flavonol quercetin, in human platelets. *Agric Food Chem* 52:4414-4418.
- Violi F. 2002. Synergism among flavonoids in inhibiting platelet aggregation and H₂O₂ production. *Circulation* 105:e53.
- Willoughby S, Holmes A, Losalzo J. 2002. Platelets and cardiovascular disease. *Eur J Cardiovasc Nursing* 1:273-288.
- Wu CM, Wu SC, Chung WJ, Lin HC, Chen KT, Chen YC, Hsu MF, Yang JM, Wang JP, Lin CN. 2007. Antiplatelet effect and selective binding to cyclooxygenase (COX) by molecular docking analysis of flavonoids and lignans. *Int J Mol Sci* 8:830-841.
- Yulizia S. 2008. Telaah Kandungan Kimia Kara Benguk (*Mucuna pruriens* DC) [Thesis]. Department of Pharmacy, ITB Central Library. ID Publisher JBPTITBPP.